The development of new anticancer agents is one of the most rapidly changing aspects of cancer research. Investigational New Drugs provides a forum for the rapid dissemination of information on new anticancer agents. The papers published are of interest to the medical chemist, toxicologist, pharmacist, pharmacologist, biostatistician and clinical oncologist. Investigational New Drugs provides the fastest possible publication of new discoveries and results for the whole community of scientists developing anticancer agents.

Each issue contains original articles dealing with anticancer drug development. Other sections are devoted to invited review articles and letters to the editor. The journal also affords the opportunity to publish the proceedings of special workshops and symposia devoted to the development of new anticancer agents. Provided they add to the understanding of the investigational agents, the journal is not adverse to publishing clinical trials with negative results.

Investigational New Drugs cuts across all the usual lines or subdisciplines, providing a locus for the presentation of relevant investigations and the discussion of critical questions appropriate to the entire field of new anticancer drug development.

100% of authors who answered a survey reported that they would definitely publish or probably publish in the journal again

Journal information

Editor-in-Chief
  • Eric K. Rowinsky
Publishing model
Hybrid. Open Access options available

Journal metrics

3.525 (2019)
Impact factor
3.384 (2019)
Five year impact factor
20 days
Submission to first decision
66 days
Submission to acceptance
207,125 (2019)
Downloads

Latest articles

Journal updates

  • COVID-19 and impact on peer review

    As a result of the significant disruption that is being caused by the COVID-19 pandemic we are very aware that many researchers will have difficulty in meeting the timelines associated with our peer review process during normal times.  Please do let us know if you need additional time. Our systems will continue to remind you of the original timelines but we intend to be highly flexible at this time.

View all updates

Subscribe

eJournal
$99.00
Note this is only the net price. Taxes will be calculated during checkout.
  • Immediate online access with complete access to all articles
  • Downloadable in PDF format
  • Subscription expires 12/31/2020

About this journal

Electronic ISSN
1573-0646
Print ISSN
0167-6997
Abstracted and indexed in
  1. BIOSIS
  2. Biological Abstracts
  3. CNKI
  4. Chemical Abstracts Service (CAS)
  5. Current Contents/ Life Sciences
  6. Current Contents/Clinical Medicine
  7. EBSCO Biomedical Reference Collection
  8. EBSCO CINAHL
  9. EMBASE
  10. Elsevier Biobase
  11. Japanese Science and Technology Agency (JST)
  12. Journal Citation Reports/Science Edition
  13. Medline
  14. Pathway Studio
  15. ProQuest ABI/INFORM
  16. ProQuest Agricultural & Environmental Science Database
  17. ProQuest Biological Science Database
  18. ProQuest Biotechnology Research Abstracts
  19. ProQuest Business Premium Collection
  20. ProQuest Central
  21. ProQuest Consumer Health
  22. ProQuest Engineering
  23. ProQuest Environmental Science
  24. ProQuest Health & Medical Collection
  25. ProQuest Health Research Premium Collection
  26. ProQuest Materials Science and Engineering Database
  27. ProQuest Medical Database
  28. ProQuest Natural Science Collection
  29. ProQuest Nursing & Allied Health Database
  30. ProQuest Pharma Collection
  31. ProQuest SciTech Premium Collection
  32. ProQuest Technology Collection
  33. Reaxys
  34. SCImago
  35. SCOPUS
  36. Science Citation Index
  37. Science Citation Index Expanded (SciSearch)
  38. Semantic Scholar
  39. UGC-CARE List (India)
Copyright information

Rights and permissions

Springer policies

© Springer Science+Business Media, LLC, part of Springer Nature